TipRanks
Advertisement
Advertisement

TRVI Stock Latest News

Trevi Therapeutics price target raised to $28 from $24 at Jones
The FlyTrevi Therapeutics price target raised to $28 from $24 at Jones
1M ago
TRVI
Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position
PremiumRatings
Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position
1M ago
TRVI
Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target
PremiumRatings
Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target
1M ago
TRVI
Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged
PremiumRatings
Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged
2M ago
TRVI
Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley
PremiumThe Fly
Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley
2M ago
TRVI
Trevi Therapeutics price target raised to $40 from $27 at Raymond James
PremiumThe FlyTrevi Therapeutics price target raised to $40 from $27 at Raymond James
2M ago
TRVI
Trevi Therapeutics price target raised to $30 from $25 at Cantor Fitzgerald
Premium
The Fly
Trevi Therapeutics price target raised to $30 from $25 at Cantor Fitzgerald
2M ago
TRVI
Trevi Therapeutics price target raised to $25 from $24 at Oppenheimer
Premium
The Fly
Trevi Therapeutics price target raised to $25 from $24 at Oppenheimer
2M ago
TRVI
Trevi Therapeutics reports Q2 EPS (11c), consensus (11c)
PremiumThe Fly
Trevi Therapeutics reports Q2 EPS (11c), consensus (11c)
2M ago
TRVI
Trevi Therapeutics Advances IPF Program with Completed NAL ER Safety Study
PremiumCompany Announcements
Trevi Therapeutics Advances IPF Program with Completed NAL ER Safety Study
2M ago
TRVI
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
PremiumThe Fly
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
2M ago
SER
TRVI
Trevi Therapeutics initiated with an Outperform at BMO Capital
PremiumThe Fly
Trevi Therapeutics initiated with an Outperform at BMO Capital
2M ago
TRVI
Trevi Therapeutics initiated with an Outperform at BMO Capital
PremiumThe FlyTrevi Therapeutics initiated with an Outperform at BMO Capital
2M ago
TRVI
Trevi Therapeutics price target raised to $31 from $21 at B. Riley
Premium
The Fly
Trevi Therapeutics price target raised to $31 from $21 at B. Riley
2M ago
TRVI
Trevi Therapeutics price target raised to $24 from $21 at H.C. Wainwright
Premium
The Fly
Trevi Therapeutics price target raised to $24 from $21 at H.C. Wainwright
2M ago
TRVI
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
PremiumThe Fly
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
2M ago
GSK
TRVI
Trevi Therapeutics rises 10.9%
PremiumThe Fly
Trevi Therapeutics rises 10.9%
2M ago
TRVI
Trevi Therapeutics rises 10.4%
PremiumThe Fly
Trevi Therapeutics rises 10.4%
2M ago
TRVI
Trevi Therapeutics management to meet with Cantor Fitzgerald
PremiumThe Fly
Trevi Therapeutics management to meet with Cantor Fitzgerald
2M ago
TRVI
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial
PremiumCompany AnnouncementsTrevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial
2M ago
TRVI
Trevi Therapeutics Targets IPF Chronic Cough With New Phase 3 Trial
Premium
Company Announcements
Trevi Therapeutics Targets IPF Chronic Cough With New Phase 3 Trial
2M ago
TRVI
Trevi Therapeutics Shareholders Approve Stock and Governance Changes
Premium
Company Announcements
Trevi Therapeutics Shareholders Approve Stock and Governance Changes
4M ago
8K
TRVI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >